# Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

> **NCT05275439** · PHASE1 · TERMINATED · sponsor: **Shattuck Labs, Inc.** · enrollment: 106 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** SL-172154
- **DRUG:** Azacitidine (AZA)
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05275439
- **Lead sponsor:** Shattuck Labs, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-17
- **Primary completion:** 2025-02-06
- **Final completion:** 2025-02-06
- **Target enrollment:** 106 (ACTUAL)
- **Why stopped:** Development discontinued
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05275439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05275439, "Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT05275439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*